Zydus和Lupin伙伴在印度共同销售酸,增加获得糖尿病和体重管理治疗的机会。 Zydus and Lupin partner to co-market semaglutide in India, boosting access to diabetes and weight management treatment.

Zydus生命科学与Lupin合作在印度共同销售酸注射,扩大获得糖尿病和体重管理治疗的机会。 Zydus Lifesciences and Lupin have partnered to co-market semaglutide injection in India, expanding access to a diabetes and weight management treatment. 该药物可在可重复使用的笔中获取,其对象是患有2型糖尿病或肥胖症的成人。 The drug, available in a reusable pen, targets adults with type 2 diabetes or obesity-related conditions. Zydus将在Semaglyntm、Mashematm和Altermetm下宣传它,而Lupin将使用Semanext和Livarise。 Zydus will promote it under Semaglyntm, Mashematm, and Altermetm, while Lupin will use Semanext and Livarise. Lupin将提前支付Zydus的里程碑收费。 Lupin will pay Zydus upfront and milestone-based fees. 合作的目的是通过综合分配和发展专门知识,改善患者获得服务的机会。 The collaboration aims to improve patient access through combined distribution and development expertise.